Yuhan

Bio & Pharma Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

Bio & Pharma Yuhan’s lung cancer drug clears FDA hurdle for global debut

A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...

Bio & Pharma Inventage Lab, Yuhan to co-work for obesity treatment

South Korea’s Inventage Lab Inc. announced on Friday that it has signed a joint development agreement with Yuhan Corp. for a long-acting inj...

Bio & Pharma J&J seeks US, European approval for drug developed with Yuhan

Global healthcare giant Johnson & Johnson is seeking approval for a lung cancer drug developed with Yuhan Corp., bringing the South Korean pha...